ReviewCancers2018
Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Natural History of Treated and Untreated Bland Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma.Cancers · 2026Article
- Tissue factor promotes vascular invasion and metastasis in hepatocellular carcinoma via combined activation of β-catenin/STAT3 signaling.Molecular biomedicine · 2026Article
- Article
- Portal Vein Thrombosis in Cirrhotic Candidates for Liver Transplantation and Its Impact on the Transplant Accessibility.Journal of clinical medicine · 2026Article
- Cardiovascular Risk and Prediction Model of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors in Patients with Liver Cancer.Cardiovascular toxicology · 2026Article
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Internal Jugular Vein Thrombosis: A Bicentric Cohort Study.Journal of clinical medicine · 2025Article
- The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis.Journal of clinical and translational hepatology · 2024Article
- FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.Journal for immunotherapy of cancer · 2024Article
- Machine learning models to predict systemic inflammatory response syndrome after percutaneous nephrolithotomy.BMC urology · 2024Article
- Portal Vein Thrombosis: State-of-the-Art Review.Journal of clinical medicine · 2024Review
- Case report: Rapid development of acute symptomatic portal vein system thrombosis after endoscopic variceal therapy in a patient with liver cirrhosis.Frontiers in medicine · 2024Article
- Editorial: Case reports in thrombosis: 2023.Frontiers in cardiovascular medicine · 2024Article
- MicroRNA-155 downregulates long noncoding RNA prostate cancer-associated transcript 29 in hepatocellular carcinoma to suppress cancer cell invasion and migration.Journal of biochemical and molecular toxicology · 2023Article
- Key therapeutic targets implicated at the early stage of hepatocellular carcinoma identified through machine-learning approaches.Scientific reports · 2023Article
- Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis.International journal of molecular sciences · 2023Review
- Map of thrombogenesis in viral infections and viral-driven tumours.Discover oncology · 2023Review
- [Exploration of pathogenesis and clinical diagnosis and treatment for portal vein thrombosis formation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Predictors of Deep Venous Thrombosis in Hospitalized Patients With Liver Cirrhosis in the US.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein being the most frequent site (PVT). However, patients with HCC are peculiar as both cancer and liver cirrhosis are conditions that can perturb the hemostatic balance towards a prothrombotic state. Because HCC-related hypercoagulability is not clarified at all, the aim of the present review is to summarize the currently available knowledge on epidemiology and pathogenesis of non-malignant thrombotic complications in patients with liver cirrhosis and HCC. They are at increased risk to develop both PVT and non-splanchnic VTE, indicating that both local and systemic factors can foster the development of site-specific thrombosis. Recent studies have suggested multiple and often interrelated mechanisms through which HCC can tip the hemostatic balance of liver cirrhosis towards hypercoagulability. Described mechanisms include increased fibrinogen concentration/polymerization, thrombocytosis, and release of tissue factor-expressing extracellular vesicles. Currently, there are no specific guidelines on the use of thromboprophylaxis in this unique population. There is the urgent need of prospective studies assessing which patients have the highest prothrombotic profile and would therefore benefit from early thromboprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.